1-4 of 4
Violeta Serra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Qing Li, Baishan Jiang, Jiaye Guo, Hong Shao, Isabella S. Del Priore, Qing Chang, Rei Kudo, Zhiqiang Li, Pedram Razavi, Bo Liu, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Katherine A. Donovan, Marta Palafox, Jorge S. Reis-Filho, Elisa de Stanchina, Eric S. Fischer, Neal Rosen, Violeta Serra, Andrew Koff, John D. Chodera, Nathanael S. Gray, Sarat Chandarlapaty
Journal: Cancer Discovery
Cancer Discov (2022) 12 (2): 356–371.
https://doi.org/10.1158/2159-8290.CD-20-1726
Published: 01 February 2022
View article titled, INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
Open the PDF for INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Suzanne Carreira, Nuria Porta, Sara Arce-Gallego, George Seed, Alba Llop-Guevara, Diletta Bianchini, Pasquale Rescigno, Alec Paschalis, Claudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Mateus Crespo, Bora Gurel, Daniel Nava Rodrigues, Stephen J. Pettitt, Wei Yuan, Violeta Serra, Jan Rekowski, Christopher J. Lord, Emma Hall, Joaquin Mateo, Johann S. de Bono
Journal: Cancer Discovery
Cancer Discov (2021) 11 (11): 2812–2827.
https://doi.org/10.1158/2159-8290.CD-21-0007
Published: 01 November 2021
View article titled, Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Open the PDF for Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial in another window
Includes: Supplementary data
Journal Articles

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation

Violeta Serra, Ana Vivancos, Xose S. Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluís Parra, Leticia De Mattos-Arruda, Judit Grueso, Javier Hernández-Losa, Joaquín Arribas, Ludmila Prudkin, Paolo Nuciforo, Maurizio Scaltriti, Joan Seoane, José Baselga
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2013) 3 (11): 1238–1244.
https://doi.org/10.1158/2159-8290.CD-13-0132
Published: 06 November 2013
View article titled, Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <em>HER2</em><sup>V659E</sup> Mutation
Open the PDF for Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <em>HER2</em><sup>V659E</sup> Mutation in another window
Includes: Supplementary data
Journal Articles

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Yasir H. Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres-Lockhart, Aleix Prat, Pilar Anton, Patricia Cozar, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maria Teresa Calvo, Claudia Aura, Orland Díez, Isabel T. Rubio, José Pérez, Jordi Rodón, Javier Cortés, Leif W. Ellisen, Maurizio Scaltriti, José Baselga
Journal: Cancer Discovery
Cancer Discov (2012) 2 (11): 1036–1047.
https://doi.org/10.1158/2159-8290.CD-11-0348
Published: 11 November 2012
View article titled, PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Open the PDF for PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition in another window
Includes: Supplementary data